title: Role of pharmacotherapy in cardiac ion channelopathies.
abstract: In the last decade, there have been considerable advances in the understanding of the pathophysiology of malignant ventricular tachyarrhythmias (VT) and sudden cardiac death (SCD). Over 80% of SCD occurs in patients with organic heart disease. However, approximately 10%-15% of SCD occurs in the presence of structurally normal heart, and the majority of these patients are young. In this group of patients, changes in genes encoding cardiac ion channels produce modifications of the function of the channel resulting in an electrophysiological substrate of VT and SCD. Collectively, these disorders are referred to as cardiac ion channelopathies. The four major syndromes in this group are: the long QT syndrome (LQTS), the Brugada syndrome (BrS), the short QT syndrome (SQTS), and the catecholaminergic polymorphic ventricular tachycardia (CPVT). Each of these syndromes includes multiple subtypes with different and sometimes complex cardiac ion channel genetic abnormalities. Many are associated with other somatic and neurological abnormalities besides the risk of VT and SCD. The current management of cardiac ion channelopathies can be summarized as follows: (1) in symptomatic patients, the implantable cardioverter defibrillator (ICD) is the only viable option; (2) in asymptomatic patients, risk stratification is necessary, followed by either the ICD, pharmacotherapy, or a combination of both. A genotype-specific approach to pharmacotherapy requires a thorough understanding of the molecular-cellular basis of arrhythmogenesis in cardiac ion channelopathies as well as the specific drug profile.
authors.affiliation: Downstate Medical Center, State University of New York, Brooklyn, NY, USA; VA NY Harbor Healthcare System, Brooklyn, NY, USA. Electronic address: nelsherif@aol.com.
authors.forename: Nabil
authors.initials: N
authors.lastname: El-Sherif
authors.affiliation: Downstate Medical Center, State University of New York, Brooklyn, NY, USA; VA NY Harbor Healthcare System, Brooklyn, NY, USA; NYU School of Medicine, New York, NY, USA.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Boutjdir
mesh_terms: D000818:Animals; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D053447:Channelopathies / Q000188:drug therapy*; D006801:Humans
keywords: Brugada syndrome; Catecholaminergic polymorphic ventricular tachycardia; Channelopathies; Long QT syndrome; Short QT syndrome; Sudden cardiac death